- Home
- SHO vs PTGX Comparison
SHO vs PTGX Comparison
Compare SHO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- PTGX
- Stock Information
- Founded
- SHO 1995
- PTGX 2006
- Country
- SHO United States
- PTGX United States
- Employees
- SHO N/A
- PTGX N/A
- Industry
- SHO Hotels/Resorts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- SHO Consumer Discretionary
- PTGX Health Care
- Exchange
- SHO Nasdaq
- PTGX Nasdaq
- Market Cap
- SHO 1.7B
- PTGX 3.3B
- IPO Year
- SHO 1995
- PTGX 2016
- Fundamental
- Price
- SHO $8.93
- PTGX $51.25
- Analyst Decision
- SHO Hold
- PTGX Strong Buy
- Analyst Count
- SHO 8
- PTGX 9
- Target Price
- SHO $9.56
- PTGX $67.11
- AVG Volume (30 Days)
- SHO 2.8M
- PTGX 1.0M
- Earning Date
- SHO 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- SHO 4.03%
- PTGX N/A
- EPS Growth
- SHO N/A
- PTGX N/A
- EPS
- SHO 0.10
- PTGX 0.86
- Revenue
- SHO $922,708,000.00
- PTGX $207,801,000.00
- Revenue This Year
- SHO $7.67
- PTGX N/A
- Revenue Next Year
- SHO $3.45
- PTGX $47.15
- P/E Ratio
- SHO $91.03
- PTGX $59.19
- Revenue Growth
- SHO N/A
- PTGX N/A
- 52 Week Low
- SHO $7.45
- PTGX $32.50
- 52 Week High
- SHO $12.41
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- SHO 54.63
- PTGX 45.80
- Support Level
- SHO $8.57
- PTGX $49.86
- Resistance Level
- SHO $9.02
- PTGX $57.24
- Average True Range (ATR)
- SHO 0.25
- PTGX 2.06
- MACD
- SHO 0.02
- PTGX -0.78
- Stochastic Oscillator
- SHO 84.75
- PTGX 16.14
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.